Epidemiologic study to assess patient involvement in choice of adjuvant chemotherapy for breast cancer (PROSA Study)

Clinical and Translational Oncology

Volumn 11, Issue 4, 2009, Pages 221-227

  Tusquets, Ignasi ^a   Arranz, Enrique Espinosa ^b   Méndez, Miguel ^c   Miquel Gil, J ^d   Guallar, José Luis ^e   Perulero, Núria ^f  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL DE MÓSTOLES   (Spain)

^d HOSPITAL DURAN I REYNALS   (Spain)

^e Centro de Investigation Basica Sanofi Aventis   (Spain)

^f IQVIA   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Patient preferences

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ALOPECIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG PREFERENCE; EDUCATION; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; PATIENT SATISFACTION; SOCIAL STATUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; MIDDLE AGED; PATHOLOGY; PATIENT PARTICIPATION; PROSPECTIVE STUDY; SPAIN; STATISTICS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT PARTICIPATION; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SPAIN; TAXOIDS;

EID: 67650264369     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0344-8     Document Type: Article

References (11)

1. Instituto de Salud Carlos III. Centro Nacional de Epidemiología. Mortalidad por Causa, Sexo y Grupo de Edad (1996-2005). ISCIII, Madrid. Accessed 21.04.08. Available from: http://www.isciii.es/htdocs/centros/ epidemiologia/mortalidad.jsp
2. Clèries R, Ribes J, Esteban L et al (2006) Time trends of breast cancer mortality in Spain during the period 1977-2001 and Bayesian approach for projections during 2002-2016. Ann Oncol 17:1783-1791
3. Smith I (2005) Adjuvant treatment for early breast cancer. Ann Oncol 16[Suppl 2]:iI182-187
4. Baile WF, Lenzi R, Parker PA et al (2002) Oncologists' attitudes toward and practices in giving bad news: An exploratory study. J Clin Oncol 20:2189-2196
5. Jansen SJT, Otten W (2004) The impact of the perception of treatment choice on satisfaction with treatment, experienced chemotherapy burden and current quality of life. Br J Cancer 91:56-61
6. Mandelblatt JS, Edge SB, Meropol NJ et al (2003) Predictors of long-term outcomes in older breast cancer survivors: Perceptions versus patterns of care. J Clin Oncol 21:855-863
7. Sweeney KJ, Ryan E, Canney M et al (2007) Justifying adjuvant chemotherapy in breast cancer: A survey of women and healthcare professionals. Eur J Surg Oncol 33:838-842
8. Buban GM, Link BK, Doucette WR (2001) Influences on oncologists' adoption of new agents in adjuvant chemotherapy of breast cancer. J Clin Oncol 19:954-959
9. Deadman JM, Leinster SJ, Owens RG et al (2001) Taking responsibility for cancer treatment. Soc Sci Med 53:669-677
10. Duric VM, Stockler MR, Heritier S et al (2005) Patients' preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now? Ann Oncol 16:1786-1794
11. Vogel BA, Bengel J, Helmes AW (2008) Information and decision making: patients' needs and experiences in the course of breast cancer treatment. Patient Educ Couns 71:79-85